Interest in Cessation Treatment Among People Who Smoke in a Community-Based Multidisciplinary Thoracic Oncology Program [0.03%]
在社区基础的多学科胸部肿瘤计划中吸烟者对戒烟治疗的兴趣
Meghan Meadows-Taylor,Kenneth D Ward,Weiyu Chen et al.
Meghan Meadows-Taylor et al.
Introduction: To evaluate the need for tobacco cessation services within a multidisciplinary clinic (MDC), we surveyed patients on their smoking status, interest in quitting, and willingness to participate in a clinic-bas...
Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib [0.03%]
简报：奥希替尼和萨沃利替尼获得性耐药机制的异质性研究
Sun Min Lim,San-Duk Yang,Sangbin Lim et al.
Sun Min Lim et al.
Introduction: MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR revealed promising results in recent clinical trials. Nevertheless, acquired resis...
EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report [0.03%]
转移性肺腺癌中EML4-ALK重排作为奥希替尼耐药的机制：病例报告
Xinyu von Buttlar,Joshua E Reuss,Stephen V Liu et al.
Xinyu von Buttlar et al.
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the preferred frontline therapy for EGFR-mutant advanced NSCLC. However, despite its high initial response rates, multiple EGFR-independent mechanisms of resistance have bee...
Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma [0.03%]
YS110（一种重组人源化抗CD26单克隆抗体）在日本晚期恶性胸膜间皮瘤患者中的二期研究
Kazuhiko Nakagawa,Takashi Kijima,Morihito Okada et al.
Kazuhiko Nakagawa et al.
Introduction: YS110, a humanized monoclonal antibody with a high affinity to CD26, exhibited promising antitumor activity and was generally well-tolerated in the phase 1 part of a phase 1 and 2 Japanese trial in patients ...
Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report [0.03%]
奥希替尼和培美曲塞对EGFR突变的转移性非小细胞肺癌脑膜病持久反应一例报告
Cristina M Merkhofer,Christina S Baik
Cristina M Merkhofer
Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertini...
Jana B Adizie,Judith Tweedie,Aamir Khakwani et al.
Jana B Adizie et al.
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes o...
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset [0.03%]
瑞姆西鲁单抗联合厄洛替尼对比安慰剂联合厄洛替尼治疗未经治疗的伴有EGFR突变的转移性非小细胞肺癌日本亚组RELAY研究
Kazuto Nishio,Takashi Seto,Makoto Nishio et al.
Kazuto Nishio et al.
Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untre...
Salvage Surgery for Patients With Local Recurrence or Persistent Disease After Treatment With Chemoradiotherapy for SCLC [0.03%]
化学放射治疗后局部复发或持续存在的小细胞肺癌患者的挽救性手术
Pieter J M Joosten,Toon A Winkelman,David J Heineman et al.
Pieter J M Joosten et al.
Introduction: The role of salvage surgery for patients with locoregional (LR) recurrence or persistent SCLC after radical chemoradiotherapy (CRT) for limited-stage disease is not well established. We evaluated our experie...
Owen W J Prall
Owen W J Prall
High-Grade Neuroendocrine Carcinoma Within a Tracheal Polyp: A Case Report [0.03%]
气管息肉中的高级别神经内分泌癌一例报告
Victor Brochu,Gurdip Singh Tamber,Roni F Rayes et al.
Victor Brochu et al.
Introduction: Primary carcinomas of the trachea are rare, with a reported annual incidence of one in a million. We present a case of a previously undescribed polypoid high-grade neuroendocrine carcinoma of the trachea. Re...